OBJECTIVES: Pharmacological ascorbate (P-AscH - , high-dose, intravenous vitamin C) has shown promise as an adjuvant therapy for pancreatic ductal adenocarcinoma (PDAC) treatment. The objective of this study was to determine the effects of P-AscH - when combined with PDAC chemotherapies. METHODS: Clonogenic survival, combination indices, and DNA damage were determined in human PDAC cell lines treated with P-AscH - in combination with 5-fluorouracil, paclitaxel, or FOLFIRINOX (combination of leucovorin, 5-fluorouracil, irinotecan, oxaliplatin). Tumor volume changes, overall survival, blood analysis, and plasma ascorbate concentration were determined in vivo in mice treated with P-AscH - with or without FOLFIRINOX. RESULTS: P-AscH - combined with 5-fluorouracil, paclitaxel, or FOLFIRINOX significantly reduced clonogenic survival in vitro. The DNA damage, measured by γH2AX protein expression, was increased after treatment with P-AscH - , FOLFIRINOX, and their combination. In vivo, tumor growth rate was significantly reduced by P-AscH - , FOLFIRINOX, and their combination. Overall survival was significantly increased by the combination of P-AscH - and FOLFIRINOX. Treatment with P-AscH - increased red blood cell and hemoglobin values but had no effect on white blood cell counts. Plasma ascorbate concentrations were significantly elevated in mice treated with P-AscH - with or without FOLFIRINOX. CONCLUSIONS: The addition of P-AscH - to standard of care chemotherapy has the potential to be an effective adjuvant for PDAC treatment.
OBJECTIVES: Pharmacological ascorbate (P-AscH - , high-dose, intravenous vitamin C) has shown promise as an adjuvant therapy for pancreatic ductal adenocarcinoma (PDAC) treatment. The objective of this study was to determine the effects of P-AscH - when combined with PDAC chemotherapies. METHODS: Clonogenic survival, combination indices, and DNA damage were determined in human PDAC cell lines treated with P-AscH - in combination with 5-fluorouracil, paclitaxel, or FOLFIRINOX (combination of leucovorin, 5-fluorouracil, irinotecan, oxaliplatin). Tumor volume changes, overall survival, blood analysis, and plasma ascorbate concentration were determined in vivo in mice treated with P-AscH - with or without FOLFIRINOX. RESULTS: P-AscH - combined with 5-fluorouracil, paclitaxel, or FOLFIRINOX significantly reduced clonogenic survival in vitro. The DNA damage, measured by γH2AX protein expression, was increased after treatment with P-AscH - , FOLFIRINOX, and their combination. In vivo, tumor growth rate was significantly reduced by P-AscH - , FOLFIRINOX, and their combination. Overall survival was significantly increased by the combination of P-AscH - and FOLFIRINOX. Treatment with P-AscH - increased red blood cell and hemoglobin values but had no effect on white blood cell counts. Plasma ascorbate concentrations were significantly elevated in mice treated with P-AscH - with or without FOLFIRINOX. CONCLUSIONS: The addition of P-AscH - to standard of care chemotherapy has the potential to be an effective adjuvant for PDAC treatment.
Authors: Brianne R O'Leary; Frederick K Houwen; Chase L Johnson; Bryan G Allen; James J Mezhir; Daniel J Berg; Joseph J Cullen; Douglas R Spitz Journal: Radiat Res Date: 2018-03-16 Impact factor: 2.841
Authors: Qi Chen; Michael Graham Espey; Andrew Y Sun; Chaya Pooput; Kenneth L Kirk; Murali C Krishna; Deena Beneda Khosh; Jeanne Drisko; Mark Levine Journal: Proc Natl Acad Sci U S A Date: 2008-08-04 Impact factor: 11.205
Authors: Jihye Yun; Edouard Mullarky; Changyuan Lu; Kaitlyn N Bosch; Adam Kavalier; Keith Rivera; Jatin Roper; Iok In Christine Chio; Eugenia G Giannopoulou; Carlo Rago; Ashlesha Muley; John M Asara; Jihye Paik; Olivier Elemento; Zhengming Chen; Darryl J Pappin; Lukas E Dow; Nickolas Papadopoulos; Steven S Gross; Lewis C Cantley Journal: Science Date: 2015-11-05 Impact factor: 47.728
Authors: Claire M Doskey; Visarut Buranasudja; Brett A Wagner; Justin G Wilkes; Juan Du; Joseph J Cullen; Garry R Buettner Journal: Redox Biol Date: 2016-10-28 Impact factor: 11.799